Schafer PH et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal.

2014;26:2016.

Hansen RB et al. Novel treatments with small molecules in psoriatic arthritis. Curr Rheumatol Rep. 2014;16:443.

Papp K et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomized controlled

trial. Lancet. 2012;380:738.

Papp K et al. Efficacy and safety of apremilast in subjects with moderate to severe plque psoriasis: results from a

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose comparison study. J Eur

Acad Dermatol Venereol. 2013;27:e376.

Saccomani C et al. Experience with biologics for psoriasis in daily practice: rotational therapy is required. J

Dermatolog Treat. 2011;22(3):151–152.

Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis.

2005;64(Suppl2):ii–74.

MollJ et al. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3:55.

Mease PJ. Psoriatic arthritis: pharmacotherapy update. Curr Rheumatol Rep. 2010;12:272.

Kingsley GH et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology.

2012;51:1368.

de Vlam K, Lories RJ. Update in treatment options for psoriatic arthritis. Expert Rev Clin Immunol. 2009;5:779.

Rosenberg P et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during

methotrexate treatment. J Hepatol. 2007;46:1111.

Reddy M et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ra expression and inhibition of IL-12- and IL-23-

induced cytokine secretion by CNTO 1275. Cell Immunol. 2007;247:1.

van de Kerkhof PC et al. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in

patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. Br J

Dermatol. 2008;159:1177.

Hsu L et al. Antidrug antibodies in psoriasis: a systematic review. Br J Dermatol. 2014;170:261–273.

Reich K et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe

psoriasis: a retrospective analysis of the EXPRESS trial. Dermatology. 2010;221:172.

Poulalhon N et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis:

evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol. 2007;156:329.

Menter A et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J

Am Acad Dermatol. 2008;58:106–115.

Griffiths C et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis

(uncover-2 and uncover-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.

Dharamsi JW et al. Using ‘number needed to treat’ to help conceptualize the magnitude of benefit and risk of

tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. Br J Dermatol. 2009;161:605.

Dawe RS. Using ‘number needed to treat’ to express the magnitudes of benefit of ultraviolet B phototherapy

and of antitumour necrosis factor-alpha therapies for psoriasis. Br J Dermatol. 2010;162:456.

Signorovitch JE et al. Comparative eddicacy of biological treatments for moderate-to-severe psoriasis: a network

meta-analysis adjusting for cross-trial differences in reference arm response. Br J Dermatol. 2015;172:504–

512.

Lin VW et al. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe

plaque psoriasis: a Bayesian network meta-analysis. Arch Dermatol. 2012;148:1403–1410.

Reich K et al. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of

randomized controlled trials. Br J Dermatol. 2012;166:179–188.

Gladman DD et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the

adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476.

Tyring S et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Arch Dermatol. 2007;143:719.

Griffiths CE et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med.

2010;362:118.

Schett et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized,

double-blind, placebo-controlled study. Arthritis Rheum. 2012;64:3156.

Kavanaugh A et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with

apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020.

Armstrong AW et al. Combining biologic therapies with other systemic treatments in psoriasis. JAMA Dermatol.

2015;151:432–438.

p. 844

PHOTOSENSITIVITY

Ultraviolet radiation (UVR) exposure has been linked to many adverse

effects, including malignant melanoma.

Case 42-1 (Questions 1, 2)

Photoprotection encompasses all methods of UVR blocking, including

sunscreens, protective clothing, and sunglasses. Sunscreens are widely

used to prevent sunburn and reduce the incidence of premature aging

and carcinogenesis, although clothing and avoiding direct sunlight offer

greater protection.

Case 42-1 (Questions 3–9)

The use of tanning beds that use artificial ultraviolet A (UVA) has not

been shown to reduce long-term damage to the skin or to provide

protection from natural UVR. The use of tanning beds should be

minimized, and adherence to Food and Drug Administration (FDA)

recommendations on length of exposure should be encouraged.

Case 42-2 (Questions 1, 2)

Sunburn is a self-limiting condition, which is generally managed with

symptomatic treatment including oral analgesics, topical analgesics, and

topical anesthetics. Treatment beyond self-management is necessary if

the sunburn is accompanied by constitutionalsymptoms, involves

second- or third-degree burns, or is infected.

Case 42-3 (Question 1)

Phototoxicity and photoallergy are often drug- or chemical-induced

reactions to UVR exposure and account for up to 8% of adverse drug

reactions.

Case 42-4 (Questions 1–3)

PHOTOAGING

Photodamaged skin is characterized as being wrinkled, yellowed, and

sagging.

Case 42-5 (Question 1)

Topical retinoid therapy is most effective for patients of 50 to 70 years

of age with moderate-to-severe photoaging and for prophylactic use in

patients undergoing the initial changes of photoaging.

Case 42-5 (Questions 2–5)

BURN INJURIES

Most burn injuries are minor and can be managed in ambulatory settings. Case 42-6 (Question 1)

Major second- or third-degree burns should be immediately triaged to a

health system with a multidisciplinary team that can adequately manage

all of the potential complications.

Case 42-6 (Question 1)

Synthetic dressings and skin substitutes have expanded the options and

the desired outcomes for recovery.

Case 42-6 (Question 2)

p. 845

p. 846

ULTRAVIOLET RADIATION (UVR) EXPOSURE

Incidence, Prevalence, and Epidemiology

Changing lifestyles have considerably increased human exposure to sunlight: more

outdoor recreational activities, more emphasis on tanning, longer life spans, seasonal

population shifts to the Sunbelt, and an emphasis on improving vitamin D deficiency.

Epidemiologic evidence clearly implicates sunlight as a causative factor in many

skin diseases, and public attitudes toward tanning and sun exposure have slowly

begun to change. Skin cancer is the most common of all cancers and yet also one of

the most preventable. Squamous cell carcinoma (SCC) and basal cell carcinoma

(BCC), which together account for more than half of all malignancies in the United

States, are linked closely to exposure to ultraviolet radiation (UVR).

1 Melanoma

incidence rates have doubled from 1982 to 2011 in the United States, with 65,647

cases in 2011 and 9,128 deaths. Without intervention, the annual cost of treating

newly diagnosed melanomas is projected to triple by 2030, but the CDC estimates

that a comprehensive national skin cancer prevention program could potentially avert

230,000 melanoma cases.

2

In July 2014, the acting Surgeon General delivered “The

Surgeon General’s Call to Action to Prevent Skin Cancer.” The purpose of the call

was to unite various sectors of the nation to address skin cancer as a major public

health problem, increase awareness of skin cancer, and call for action to reduce

risk.

3

Sunburn, photoaging, immunologic changes in the skin, cataracts, photodermatoses,

phototoxicity, and photoallergy are other commonly encountered photosensitivity

reactions that occur after UVR exposure. Phototoxicity and photoallergy are often

drug- or chemical-induced reactions to UVR exposure and account for up to 8% of

adverse drug reactions.

4 The appropriate use of sunscreens or other photoprotective

behaviors can help mitigate the incidence of the adverse effects of UVR. Despite this

fact, sunscreen use remains low, with recent survey-based estimates showing that

fewer than 15% of men and 30% of women use sunscreen on both the face and the

exposed skin as recommended. Forty-two percent of men reported never using

sunscreen at all.

5

Etiology

ULTRAVIOLET RADIATION SPECTRUM

Ultraviolet radiation, the primary inducer of photosensitivity reactions in humans, is

divided into ranges according to the effects of four primary wavelengths: UVA1

(340–400 nm), UVA2 (320–340 nm), UVB (290–320 nm), and UVC (200–290 nm)

(Fig. 42-1; Table 42-1). UVA, with a wavelength of 320 to 400 nm, is closest in

wavelength to visible light.

6 UVA radiation levels have small fluctuations during the

day and are present from sunrise to sunset every day, all year round, even in the

winter and on cloudy days. UVA is considerably less likely than a comparable dose

of UVB to cause a similar degree of erythema.

7,8

In contrast to UVB, UVA penetrates

into the dermal layer and may cause harmful effects not caused by UVB.

5 About 10 to

100 times more UVA reaches the earth’s surface than UVB. Consequently, UVA may

contribute up to 15% of the erythemal response at midday.

6,9 UVB is the most

erythemogenic and melanogenic of the three UVR bands.

6,10 Up to 90% of UVB is

blocked by the earth’s stratospheric ozone layer, and it is absorbed completely by the

epidermal layer of the skin.

11,12

In addition, UVB radiation can alter the immune

system,

12

thereby increasing the incidence of certain cancers, including skin cancers.

The only known beneficial effect of UVR in humans is exposure to small amounts of

UVB, most commonly through sunlight, which converts 7-dehydrocholesterol to

cholecalciferol (vitamin D3

). Vitamin D enhances calcium homeostasis and has direct

and indirect effects on cells involved with bone remodeling. As a result, vitamin D

can decrease the risk of rickets in childhood and fractures and osteomalacia in

adults.

13

The UVC wavelengths are absorbed completely by the earth’s stratospheric ozone

layer. Artificial sources of UVC have been used in the sterilization and preservation

of food and in minimizing bacterial growth in laboratories and hospital operating

rooms by germicidal lamps, which can cause erythema or cataracts if mishandled.

6,10

ENVIRONMENTAL EFFECTS ON UVR

Ozone and Chlorofluorocarbons

The amount of UVR that reaches the earth’s surface is influenced by many factors.

Concern has been focused on the implications of depletion of the ozone layer caused

by man-made pollutants such as chlorofluorocarbons (CFCs), nitrous oxide, and

other greenhouse gases (GHGs).

9,14

In the decade after this effect was first detected in

1983, ozone levels above the Antarctic had fallen to 50% of normal.

14

In the early

1990s, worldwide estimates from the Environmental Protection Agency (EPA)

predicted that for every 1% decrease in ozone, UVB radiation reaching the earth’s

surface would increase by 2% per year, possibly resulting in a 1% to 3% increase

per year in nonmelanoma skin cancer.

15 However, further research is needed to

determine whether this prediction has been realized.

16 As GHGs contribute to ozone

depletion, and because UVA is only slightly filtered by the ozone layer, any decrease

in the ozone layer would result in a disproportionate increase in UVB reaching the

earth.

Figure 42-1 Ultraviolet radiation (UVR) spectrum. *Erythrogenic and melanogenic bands of UVR.

p. 846

p. 847

Table 42-1

Types of Ultraviolet Radiation and Characteristics

Radiation Wavelength (nm) Characteristics

UVA1 (long UVA; long-wave

radiation)

340–400 Not absorbed by the ozone layer

Passes through glass

Produces some tanning, photoaging, and skin

cancers

Lower carcinogenic potential than UVA2, but

harmful over long-term exposure

Levels remain relatively constant throughout the

day

UVA2 (short UVA) 320–340 Similar characteristics to UVA1, but greater

carcinogenic potential with erythema production

similar to UVB

UVB (sunburn range of radiation) 290–320 Partially absorbed by the ozone layer before

reaching earth

Does not pass through glass

Causes erythema, sunburn, tanning, wrinkling,

photoaging, skin cancers

Daily and seasonal variation, with highest

intensity at noon

Time of Day, Cloud Cover, and Surface Reflection

The time of day influences the amount of UVR reaching the earth’s surface; 20% to

30% of the total daily UVR is received from 11 AM to 1 PM, with 75% between 9 AM

and 3 PM. Cloud cover can decrease UV intensity by 10% to 80% and decreases

infrared radiation to an even greater extent. This greater attenuation of infrared

radiation by cloud cover can lead to an increased risk of UVR overexposure because

less infrared radiation will be absorbed by the body and transformed into heat,

resulting in less warning of overexposure to UVR. In general, whenever someone’s

shadow is shorter than his or her height, care should be taken; the shorter the shadow,

the more likely a sunburn will occur. Reflection of UVR by substances (e.g., sand,

water, snow) also may be important. For example, sand reflects about 25% of

incident UVB radiation; therefore, sitting under an umbrella at the beach may not

offer adequate protection. Fresh snow can reflect 50% to 95% of incident sunlight.

Water reflects approximately 5% of erythemal UVR, whereas 75% of the radiation is

transmitted through 2 m of water, offering swimmers little protection.

6 Seasonal

changes, geographic latitude, and altitude also influence the amount of UVR reaching

the earth’s surface.

UV Index

The UV Index/Global UV Index (http://www.epa.gov/sunwise/uvindex.html),

developed by the EPA, the National Weather Service, and the Centers for Disease

Control and Prevention, is a public health education service that is calculated on a

next-day basis for every ZIP code across the United States, and worldwide.

17 This

index, with a scale from 1 (low exposure) to 11+ (extremely high exposure),

forecasts the probable intensity of skin-damaging UVR expected to reach the surface

during the noon hour when the sun is highest in the sky. Theoretically, the UV Index

can range from 0 (e.g., during the night) to 15 or 16 (in the tropics at high elevations

under clear skies). The higher the UV Index, the greater the dose received of skinand eye-damaging UVR, and the less time it takes before skin damage occurs.

The amount of UVR exposure needed to damage an individual’s skin is affected by

the elevation of the sun in the sky, the amount of ozone in the stratosphere, and the

amount of clouds present. Clear skies transmit 100% of UVR to the earth’s surface,

with scattered clouds transmitting 89%, broken clouds, 73%, and overcast clouds,

32%. The darker an individual’s skin tone, the longer (or the more UVR) it takes to

cause erythema.

Pathophysiology

ERYTHEMA, SUNBURN, AND TANNING

Erythema and Oxygen Free Radicals

Excessive exposure of the epidermal and dermal layers of the skin to UVR can result

in an inflammatory erythematous reaction. Excess UVA and UVB cause the release of

vasodilatory mediators (e.g., histamine, prostaglandins, cytokines), resulting in

increased blood flow, erythema, tissue exudates, swelling, increased sensation of

warmth, and a characteristic sunburn.

6,10 Severe UVR exposure, primarily UVB, can

cause blister formation, desquamation, fever, chills, weakness, and shock. Erythema

caused by UVB begins within 3 to 5 hours after exposure, is maximal after 12 to 24

hours, and usually resolves during the ensuing 3 days.

10

In contrast, erythema caused

by UVA begins immediately, plateaus between 6 and 12 hours, and remains for 24

hours. UVA-induced changes in the dermis are characterized by greater damage to the

vasculature and dense cellular infiltrates that penetrate to deeper levels of the skin.

10

The dermis also may be damaged when endogenous components of the skin absorb

UVR energy and subsequently interact with oxygen to form tissue-damaging oxygen

free radicals.

11

Histology of Sunburn

The skin undergoes adaptive changes in response to UVR exposure.

When keratinocytes in the epidermis are damaged and lose their typical

organization, both the epidermis and the stratum corneum thicken and attempt to serve

as a barrier to UVR, particularly to UVB.

9 The skin’s normal protective immune

response, however, is altered with exposure to UVR. Metalloproteinase proteins act

as proteolytic enzymes that are produced from low-dose UVR

p. 847

p. 848

exposure, causing degradation of collagen and elastin in the dermal matrix.

18

Langerhans cells (i.e., antigen-presenting cells in the skin) are decreased in number

and function even after small doses of UVB.

18 These cells abnormally activate

suppressor T lymphocytes and lose their ability to activate normal effector pathways

of the immune system.

19

Immediate Pigment Darkening and Delayed Tanning

Tanning is an adaptive mechanism of the skin to UVR. Tanning occurs by two

different mechanisms: immediate pigment darkening (Meirowsky phenomenon) and

delayed tanning. The primary cell involved in tanning is the melanocyte, which

produces the radiation-absorbing protein melanin.

6,9

Immediate pigment darkening

begins during the actual exposure to UVA and certain bands of visible light,

6,9 and the

oxidation of existing melanin in the epidermis transiently turns the skin grayish

brown. The degree of immediate pigment darkening depends on the duration and

intensity of exposure, the extent of previous tanning (or amount of preexisting

melanin), and the skin type of the individual.

5

Immediate pigment darkening is not

protective against UVB erythema.

9

Delayed tanning occurs 48 to 72 hours after exposure to either UVA or UVB. It is

most intense 7 to 10 days after UV exposure and can last for weeks to months.

6

Delayed tanning is the result of increased production of melanin, an increase in the

size of dendritic processes, increased melanization of melanosomes, and an increase

in the rate of transfer of melanosomes (particulate bodies of melanin) to

keratinocytes.

6,9 The keratinocyte, now pigmented with melanosomes, migrates to the

epidermis, producing the characteristic suntan. Delayed tanning caused by UVA is

less protective against sunburn than delayed tanning caused by UVB, because

epidermal thickening is not induced by UVA.

6

PHOTOCARCINOGENESIS

Squamous Cell and Basal Cell Carcinoma

The association between skin cancer in humans and UVR exposure is based primarily

on clinical and epidemiologic evidence. Nonmelanoma skin cancers, such as SCC

and BCC, occur most commonly on areas that are maximally exposed to sunlight

(e.g., the face, neck, arms, back of the forearms, and hands).

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more